Since its spin-off from Celanese in 1986, Celgene (CELG) has built an active pipeline of drugs that focus on treatments for cancer and inflammatory diseases. Additionally, its acquisitions of Receptos in 2015 and Delinia in 2017 have created huge prospects for the company. Celgene is expected to submit new drug application for Ozanimod in 2017.
Blockbuster products with strong sales and earnings growth
Celgene has four blockbuster products that have global presence - Revlimid, Pomalyst, Otezla and Abraxane. Collectively, these products have shown a double digit year-over-year growth in past four years.
